Physicians' Academy for Cardiovascular Education

A novel approach for high CV risk patients with diabetes: The potential of epigenetics

Meeting report with video, highlights and slides of PACE-CME symposium held during ESC 2016 in Rome on the potential role of epigenetics in patients with high CV Risk and diabetes

Meeting Impression: A novel approach for high CV risk patients with diabetes: The potential for epigenetics

News - Sep. 6, 2016
A novel Approach for high CV risk patients with diabetes: The potential for epigenetics and apabetalone

A Meeting Impression from a EBAC accredited satellite symposium held at ESC 2016 in Rome that explored a novel approach to reduce residual CV risk, namely BET inhibition

BET inhibition in cardiovascular disease: A new dawn?

Literature - Aug. 28, 2016 - John Kastelein, MD - Academic Medical Centre, Amsterdam, The Netherlands

At the 'A novel approach for high cv risk patients with diabetes: the potential of epigenetics' symposium, held at the ESC Congress 2016 in Rome, John Kastelein spoke about the first results of BET inhibition as a new therapy to lower CV risk.

The high risk diabetes patient with cardiovascular disease: What else can we target to reduce cardiovascular risk?

News - Aug. 28, 2016

At the 'A novel approach for high cv risk patients with diabetes: the potential of epigenetics' symposium, held at the ESC Congress 2016 in Rome, Kausik Ray spoke about therapeutic targets to further lower CV risk.

Understanding BET inhibition as a novel pathway for cardiovascular risk modulation

Jorge Plutzky, MD - Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA

Literature - Aug. 28, 2016 - Jorge Plutzky, MD - Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA

At the 'A novel approach for high cv risk patients with diabetes: the potential of epigenetics' symposium, held at the ESC Congress 2016 in Rome, Jorge Plutzky spoke about BET inhibition as a nover pathway for CV risk reduction.